Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer

(Fred Hutchinson Cancer Research Center) The US Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. Avelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news